A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal Fistulas

Anal Fistula Clinical Trial

Official title:

A Prospective, Multi-Center, Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02, For the Management of Anal Fistulas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05641844
• Other study ID #: RD014
• Status: Recruiting
• Phase: N/A
• Start date: January 20, 2024
• Est. completion date: February 2026

Study information

• Verified date: June 2024
• Source: RedDress Ltd.
• Contact: Sharon Sirota
• Phone: +972-54-580-0765
• Email: sharon[@]reddress.co.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to assesses the safety of autologous RD2 Ver.02 as compared to a control for managing transsphincteric and intersphinsteric anal fistulas.

The main questions it aims to answer are:

Assess the safety and efficacy of RD2 Ver.02 in anal fistula application, compared to control.

Complication rate by 6 months of anal fistula treatment with RD2 Ver.02 compared to control.

Recurrence of anal fistula at 12 months post-treatment Incidence of perirectal infection by 6 months in anal fistulas treated with RD2 Ver.02 compared to control.

Patients will be randomized in to 2 arms. For all patients, blood will be drawn to ensure the blinding of the patients, the fistula will be evaluated and debrided, and then the internal fistula opening will be suture-closed, and a water leak test will be performed to ensure sealing. Following the water leak test, In the treatment arm, the patient's own coagulating blood will be applied into the entire fistula tract, allowing it to clot and serve as a provisional matrix inside the fistula tract. In the control arm, the blood sample will be discarded and saline will be applied to the fistula tract.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: February 2026
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is =18 years of age

• Subject has a transsphincteric or long intersphincteric anal fistula (>1.5 cm), with a seton in place for a minimum of 1 month, deemed eligible for primary or repeat fistula repair by anorectal advancement flap or LIFT: Anterior, posterior or lateral fistula, first or recurrent, at any position circumferentially, with one external opening and one internal opening, involving >20% of anal sphincter.

• Subjects is unable or unwilling to receive invasive surgical procedures, anorectal advancement flap or LIFT procedure, and is opting for minimally invasive technique of anal fistula management (i.e., fistula tract debridement and suturing of internal opening).

• Prior to enrollment, during the preceding 3 months subject must undergo a pelvic MRI to document intersphincteric or transsphicnteric fistula and absence of underlying abscess

• Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study and for 6 months following study procedure (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women)

Exclusion Criteria:

• Subject who has a life expectancy of less than 24 months.

• Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the informed consent form.

• Cannot withdraw blood in the required amount (up to 15 mL).

• Women who are pregnant or currently breast feeding.

• Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic steroids (more than 10mg per day).

• Multiple fistula tracts, as confirmed on pelvic MRI

• Short fistula tract that in the surgeon's opinion are amenable to fistulotomy

• Active infection including perianal infection, and/or any active systemic or local infection.

• Presence of a perirectal abscess on pelvic MRI

• Presence of dominant luminal active Crohn's disease, validated by recent colonoscopy from preceding 12 months, requiring immediate therapy

• Rectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure.

• Known allergies or hypersensitivity to any of the following: antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast); Known hypersensitivity to reagents and components of RD2 Ver.02 including calcium gluconate, Kaolin or citrate and ethylene oxide.

• Contraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements, or severe claustrophobia).

• Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. Subjects who are taking Coumadin, Aspirin, Plavix (Clopidogrel), Eliquis or Pradaxa will not be excluded.

• Patients with increased risk for the surgical procedure or major alteration of any of the following laboratory tests:

Serum Creatinine levels >1.5 upper limit of normality (ULN) Total bilirubin >1.5 ULN (unless predominantly non conjugated due to documented history of Gilbert's syndrome) AST/ ALT >3.0 ULN Hemoglobin <10.0 g/dL Platelets <150.0 x109/L Albuminemia <3.0 g/dL.

• Patients who do not wish to or cannot comply with study procedures.

• Patients currently receiving or having received within 12 months prior to enrolment into this clinical study, any investigational drug.

• Subjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration.

• Contraindication to the anesthetic procedure.

• Subject with a diagnosis of Ulcerative Colitis

• Subject with malignancy, undergoing active treatment

• Rectovaginal fistula

• History of pelvic radiation

Related Conditions & MeSH terms

• Anal Fistula
• Fistula
• Rectal Fistula

Intervention

Device:
• RD2 Ver.02
Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.

Other:
• Saline
Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.

Locations

Country	Name	City	State
Israel	Sheba Medical Center	Ramat Gan
United States	University of Chicago	Chicago	Illinois
United States	Franciscan Health	Indianapolis	Indiana
United States	Karen Zaghiyan, M.D	Los Angeles	California
United States	Lenox Hill Hospital	New York	New York
United States	Allegheny Health Network	Pittsburgh	Pennsylvania
United States	Brown surgical associates	Providence	Rhode Island
United States	Cleveland Clinic	Weston	Florida
United States	UMAS	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
RedDress Ltd.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of device-related adverse events in patients treated with RD2 Ver.02	Overall incidence and severity of Adverse Events (AEs) in RD2 Ver.02 treatment group	12 months
Other	Incidence of adverse events compared between RD2 Ver.02 and control arms	Comparison of the AEs between RD2 Ver.02 and control treatment groups	12 months
Primary	Combined healing rate at 6 months of anal fistulas treated with RD2 Ver.02 compared to control	Fistula healing will be assessed by both a blinded clinical assessor and confirmation by MRI. Healing clinical assessment is defined as the absence of any anal symptom, with no discharge from the fistula and a closed external opening. Results will be confirmed by central blinded MRI assessment.	6 months after anal fistula treatment per subject
Secondary	Recurrence of anal fistula at 12 months post-treatment in subjects with healed fistula treated with RD2 Ver.02 compared to control, to evaluate the long-term efficacy of RD2 Ver.02 Application.	Assessed by the blinded clinical assessor for fistula recurrence 12 months post procedure	12 months
Secondary	Incidence of perirectal infection by 6 months in anal fistulas treated with RD2 Ver.02 compared to control.	Infection assessment of the anal fistula	6 months